NeuroVive partners with Isomerase Therapeutics to develop new molecules
NeuroVive Pharmaceutical CEO Mikael Brönnegård said that the partnership with Isomerase Therapeutics for the molecules recently acquired from Biotica marks the beginning of expansion of its product range.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.